A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al. · Oncology · 2013 · 13.2K citations · Full text

Medicine, Cancer Biology, Oncology +17

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

The Lancet · 2011 · 3.1K citations · Full text

Medicine, Endocrinology, Oncology +15

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Medicine, Endocrinology, Oncology +14

Molecular Determinants for the Tissue Specificity of SERMs

Yongfeng Shang, Myles Brown · Science · 2002 · 1.1K citations

Life Sciences, Molecular Biology, Pharmacology +17

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

Anthony Howell, J.F.R. Robertson, J. Albano et al. · Journal of Clinical Oncology · 2002 · 669 citations

Medicine, Oncology, Pharmacology +14